The WHO said that the Solidarity trial looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical

Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients

Remdesivir is one of the few medicines believed to be effective in treating coronavirus patients. So far, it has secured approvals for emergency use from US FDA and conditional approval from the European Commission.

Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for \"restricted emergency use\" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection

Coronavirus update: The first batch of 10,000 vials had been printed with a price of 4,000 rupees, 800 rupees below the cheapest option, launched by European competitor Mylan this week

Various medical shops have been telling buyers that the medicine is in short supply but can be made available If they are ready to pay a premium, DCGI has been informed

DGCI has asked all state drug controllers to instruct their field officials to keep strict vigil to prevent black marketing and unauthorised sale of remdesivir

DRDO has built a new temporary hospital with 1000 beds, including 250 ICU beds, in Delhi. The facility was constructed in just 11 days near the Indira Gandhi International (IGI) airport, on a piece of land belonging to the Ministry of Defence, for the treatment of coronavirus patients. The construction is a collaborative effort of DRDO and Tata Sons. Watch the video for more.Also Read: Coronavirus treatment: Mylan to offer remdesivir in India at Rs 4,800

Mylan has been licensed by Gilead for marketing the drug in 127 low- and middle-income countries, including India. The company will manufacture remdesivir at its injectables facilities in India

Coronavirus drug updates: The next batch of Hetero's Remdesivir will be sent to Kolkata, Lucknow, Patna, Indore, Bhopal, Bhubaneshwar, Ranchi, Kochi, Trivandrum, Vijayawada and Goa

These two companies have been approved at a time when coronavirus cases in India are spiralling like never before and putting tremendous pressure on our healthcare system

Remdesivir can be administered to patients with moderate disease (those on oxygen), though it should not administered to patients with severe renal impairment, pregnancy or lactating females and children, health ministry guidelines suggest

Four companies -- Hetero, Jubilant Life Sciences, Cipla and Mylan NV -- with which the original drug maker, Gilead Sciences Inc, have entered into non-exclusive licensing agreements are still awaiting nod from the DCGI for manufacturing and selling of remdesivir in India

A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug

Kiran Mazumdar-Shaw expressed her anxiousness over the community spread in India. She said that several migrants who have gone back home could be asymptomatic

Cipla's net profit during the March quarter of FY20 took a beating on account of the coronavirus pandemic. The company posted a 33 per cent decline in consolidated net profit during the quarter ended March 2020

Gilead on Tuesday said it had signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of remdesivir in more than 120 mostly low-income countries in Southeast Asia, Africa and other parts of the world

'China's got to figure out how to deal with its public health because we cannot have another one of these virus outbreaks and plagues come from China,' US National Security Advisor Robert O'Brien said

Under licencing agreements with Gilead Sciences, these companies have a right to receive a technology transfer for Remdesivir to enable them to scale up production more quickly; they can also set their prices for generic product they produce